139 related articles for article (PubMed ID: 19194363)
1. DNA hypomethylation therapies and hemoglobin disorders. [An interview with Hassana Fathallah by H&O].
Fathallah H
Clin Adv Hematol Oncol; 2008 Nov; 6(11):806-8. PubMed ID: 19194363
[No Abstract] [Full Text] [Related]
2. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
Pearson HA
Adv Pediatr; 1996; 43():309-34. PubMed ID: 8794181
[No Abstract] [Full Text] [Related]
3. Pharmacological induction of fetal hemoglobin synthesis using histone deacetylase inhibitors.
Cao H
Hematology; 2004 Jun; 9(3):223-33. PubMed ID: 15204104
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.
Musallam KM; Taher AT; Cappellini MD; Sankaran VG
Blood; 2013 Mar; 121(12):2199-212; quiz 2372. PubMed ID: 23315167
[TBL] [Abstract][Full Text] [Related]
5. Approaches to the reactivation of hemoglobin F as a treatment for sickle cell disease.
DeSimone J
Clin Adv Hematol Oncol; 2004 Jan; 2(1):23-4. PubMed ID: 16163154
[No Abstract] [Full Text] [Related]
6. DNA hypo-methylating agents and sickle cell disease.
Saunthararajah Y; Lavelle D; DeSimone J
Br J Haematol; 2004 Sep; 126(5):629-36. PubMed ID: 15327513
[TBL] [Abstract][Full Text] [Related]
7. Increasing fetal hemoglobin in sickle cell disease: comparisons of 5-azacytidine (subcutaneous or oral) with hydroxyurea.
Dover GJ; Charache S; Boyer SH
Trans Assoc Am Physicians; 1984; 97():140-5. PubMed ID: 6085527
[No Abstract] [Full Text] [Related]
8. Therapies to increase fetal hemoglobin in sickle cell disease.
Steinberg MH
Curr Hematol Rep; 2003 Mar; 2(2):95-101. PubMed ID: 12901139
[TBL] [Abstract][Full Text] [Related]
9. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
Okam MM; Ebert BL
Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological induction of fetal hemoglobin: Why haven't we been more successful in thalassemia?
Fathallah H; Sutton M; Atweh GF
Ann N Y Acad Sci; 2005; 1054():228-37. PubMed ID: 16339670
[TBL] [Abstract][Full Text] [Related]
11. Seeking a way to alleviate sickle cell disease.
Mitka M
JAMA; 2002 Oct 23-30; 288(16):1970. PubMed ID: 12387636
[No Abstract] [Full Text] [Related]
12. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
[TBL] [Abstract][Full Text] [Related]
13. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
14. Exposure to hydroxyurea during pregnancy in sickle-beta thalassemia: a report of 2 cases.
Italia KY; Jijina FF; Chandrakala S; Nadkarni AH; Sawant P; Ghosh K; Colah RB
J Clin Pharmacol; 2010 Feb; 50(2):231-4. PubMed ID: 19797538
[No Abstract] [Full Text] [Related]
15. Reversing ontogeny.
Bunn HF
N Engl J Med; 1993 Jan; 328(2):129-31. PubMed ID: 7677964
[No Abstract] [Full Text] [Related]
16. Hydroxyurea and sickle cell disease.
Orringer EP; Parker JC
Hematol Pathol; 1992; 6(4):171-8. PubMed ID: 1283391
[No Abstract] [Full Text] [Related]
17. DNMT inhibitors and HDAC inhibitors regulate E-cadherin and Bcl-2 expression in endometrial carcinoma in vitro and in vivo.
Yi TZ; Li J; Han X; Guo J; Qu Q; Guo L; Sun HD; Tan WH
Chemotherapy; 2012; 58(1):19-29. PubMed ID: 22343305
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic induction of fetal hemoglobin production.
Atweh G; Fathallah H
Hematol Oncol Clin North Am; 2010 Dec; 24(6):1131-44. PubMed ID: 21075284
[TBL] [Abstract][Full Text] [Related]
19. Hemoglobin--from F to A, and back.
Adamson JW
N Engl J Med; 1984 Apr; 310(14):917-9. PubMed ID: 6199671
[No Abstract] [Full Text] [Related]
20. Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease.
Saunthararajah Y; DeSimone J
Semin Hematol; 2004 Oct; 41(4 Suppl 6):11-6. PubMed ID: 15534852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
